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Biallelic Mutations of Methionyl-tRNA Synthetase
Cause a Specific Type of Pulmonary Alveolar
Proteinosis Prevalent on Re´union Island
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Bettina Lorenz-Depiereux,5 Laurent Enaud,8 Elisabeth Graf,5 Jean Christophe Dubus,9
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Methionyl-tRNA synthetase (MARS) catalyzes the ligation of methionine to tRNA and is critical for protein biosynthesis. We identified
biallelic missense mutations in MARS in a specific form of pediatric pulmonary alveolar proteinosis (PAP), a severe lung disorder that is
prevalent on the island of Re´union and the molecular basis of which is unresolved. Mutations were found in 26 individuals from
Re´union and nearby islands and in two families from other countries. Functional consequences of the mutated alleles were assessed
by growth of wild-type and mutant strains and methionine-incorporation assays in yeast. Enzyme activity was attenuated in a liquid
medium without methionine but could be restored by methionine supplementation. In summary, identification of a founder mutation
inMARS led to themolecular definition of a specific type of PAP andwill enable carrier screening in the affected community and possibly
open new treatment opportunities.Pulmonary alveolar proteinosis (PAP) is characterized by
an accumulation of lipoproteins in the pulmonary alveoli;
this accumulation leads to restrictive lung disease and res-
piratory failure.1–3 PAP is either acquired or inherited in
an autosomal-recessive mode. The acquired form (MIM:
610910) affects adults and is attributed to granulocyte-
macrophage colony-stimulating factor (GM-CSF) autoanti-
bodies.4,5 Inherited PAP is usually diagnosed in early
childhood. So far, rare mutations in CSF receptor genes
CSF2RA (MIM: 306250) and CSF2RB (MIM: 138981) have
been reported as a cause of inherited forms (MIM:
300770, 614370). 6–8 A specific, severe childhood form of
PAP is prevalent on Re´union Island, where the incidence
is at least 1 in 10,000 newborns.1,2 Mutations in CSF2RA
and CSF2RB have been excluded previously.1 Since 1970,
approximately 34 children have been diagnosed and
treated. If a founder mutation is assumed, the most recent
common ancestor of these children can be traced back to
the early 18th century.1 The main symptom is respiratory
insufficiency, often leading to death in childhood or
adolescence as a result of lung fibrosis despite supportive
treatment, including regular whole-lung lavages (Table
S1). In addition to lung fibrosis, non-life-threatening liver
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DNA samples from individuals who were from Re´union
or the nearby islands of Comoros and Madagascar and
who were affected with unexplained PAP, and we per-
formed homozygosity mapping and exome and whole-
genome sequencing to identify the genetic basis of this
disease (Table S2). In addition, we analyzed DNA from a
Tunisian sibling pair and from an individual who has
sporadic PAP and is living in Paris.9 Written informed con-
sent was obtained from all study participants. The study
was approved by the Comite´ de Protection des Personnes
Iˆle de France II ethical review board.
We performed SNP-array genotyping in 14 affected indi-
viduals from the Re´union and Comoros islands by using
HumanOmni2.5-4 v.1 and CNV370-Duo v.1 SNP arrays
(Illumina); this enabled us to map a homozygous region
to chromosome 12q13.3 in all investigated individuals.
This region comprised 530 kb between markers rs703817
and rs2277324 (Figure S1) and contained 20 genes. Results
from additional SNP genotyping in the two affected sib-
lings from Tunisia were compatible with these findings.
Both siblings were homozygous within the critical region
on 12q13.3; however, they carried a haplotype different
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Figure 1. MARS Variants in PAP
(A) Sequencing reads showing the different
biallelic variants identified in individuals
from Re´union, Tunisia, and France.
(B) Amino acid conservation across MARS
orthologs.
(C) Scheme of the domain structure of MARS
with the location of the variants.
(D) Predicted tertiary structure. MARS con-
tains a nucleotide-binding (Rossmann) fold
(green); a region called the connective poly-
peptide, which contains the zinc-binding
sites (orange); the stem-contact fold domain
(red); and the a-helix bundle domain that
forms the anticodon-binding site (violet).
The positions of the variants are indicated
relative to the reference sequence (GenBank:
NM_004990.3). The structure of human
MARS was predicted by homology modeling
based on the Aquifex aeolicus structure of
MARS complexed with methionyl sulfamoyl
adenosine (MSA) and the elongator tRNAMet
(PDB: 2CT8)10 as templates. The model was
constructed with the SWISS-MODEL auto-
mated protein-structure homology-modeling
server. The predicted structure was super-
imposed with MSA and tRNAMet with
SPDBviewer and was visualized with Rasmol.We performed exome sequencing on two individuals
from Re´union and one of the Tunisian siblings to identify
possible disease-causing variants. Sequencing was per-The American Journal of Humformed via 100-bp paired-end reads on
HiSeq2500 systems (Illumina). We
generated, on average, 11.3 Gb of
sequence, resulting in an average depth
of coverage of 135 and in 94% of the
target regions’ being covered at least
20 times. Single-nucleotide variants
(SNVs) and small insertions and dele-
tions were called with SAMtools and
Pindel and filtered so that only those
variants with a minor-allele frequency
(MAF) of less than 1% remained. As con-
trols for filtering, we used 4,000 in-
house exomes from individuals with
unrelated diseases (Figure S2), the 1000
Genomes Project data (n ¼ 1,700), and
the Exome Aggregation Consortium
(ExAC) Browser dataset (n ¼ 60,706).
Rare variants common to all three
affected individuals were only detected
in methionyl-tRNA synthetase (MARS
[MIM: 156560]), one of the 20 genes in
the critical region. Three additional
missense variants in the critical region
had an allele frequency of at least
0.21 (Table S3). The individuals from
Re´union, Comoros, and Madagascar
islands carried two homozygous
missense variants (GenBank: NM_004990.3): c.1177G>A (p.Ala393Thr; rs141340466) and
c.1700C>T (p.Ser567Leu; rs143592405), in exons 10
and 14, respectively. The sibling pair from Tunisia carriedan Genetics 96, 826–831, May 7, 2015 827
Table 1. Variants Identified in MARS
Origin of Individuals Zygosity Genome cDNA Protein PPH2 SIFT CADD
Re´union or Comoros homozygous chr12: g.57906083C>T c.1700C>T p.Ser567Leu benign 0.68 17.38
chr12: g.57894189G>A c.1177G>A p.Ala393Thr benign 0.16 17.63
Tunisia homozygous chr12: g.57906594A>T c.1814A>T p.Asp605Val probably damaging 0 26.2
France heterozygous chr12: g.57906083C>T c.1700C>T p.Ser567Leu benign 0.68 17.38
chr12: g.57894189G>A c.1177G>A p.Ala393Thr benign 0.16 17.63
heterozygous chr12: g.57892346A>G c.1031A>G p.Tyr344Cys probably damaging 0 23.9
The human genome assembly hg19 (CRCh37) and transcript NM_004990.3 were used as reference sequences. SIFT values below 0.05 are predicted to have
functional impact. For CADD, phred-like scores (scaled C scores) are listed.a different homozygous missense variant, c.1814A>T
(p.Asp605Val), in exon 15 (Figure 1, Table 1, and Table
S2). The results from Sanger and/or exome sequencing in
the remaining 12 affected individuals used for homozygos-
ity mapping and in 12 additional affected individuals from
Re´unionwere consistentwith the initial findings. Avariant,
p.Asp605Gly, was present in a heterozygous state in a single
sample of East Asian origin out of the approximately 65,000
samples used for filtering. The variants p.Ala393Thr and
p.Ser567Leu carried by the individuals from Re´union were
found in four exomes of African origin in the ExAC dataset.
In addition, the variant p.Ala393Thr was present in 19 of
4,327 exomes of East Asian origin and in a single exome of
different origin. The frequency of the variants p.Ala393Thr
and p.Ser567Leu in 1,000 control subjects from Re´union
was 22 in 2,000 alleles, resulting in a predicted disease
frequency of 1 in 8,264, which is consistent with the
observed disease frequency on Re´union. Control subjects
were randomly chosen from the Re´unionDNAbank,which
contains DNA from individuals referred to the Centre
Hospitalier Universitaire de la Re´union because of various
diagnoses. Individuals with lung diseases were excluded.
Searching for additional disease-causing variants, we
sequenced an additional affected individual living in Paris.
SNP genotyping was consistent with a constellation in
which this individual carried two different haplotypes in
the critical region and in which one of these haplotypes
was identical with the Re´union haplotype. Indeed, we de-
tected the two variants of the Re´union haplotype and an
additional heterozygous non-synonymous substitution,
c.1031A>G (p.Tyr344Cys), in exon 9 (Figure 1, Table 1);
this substitution was present in a heterozygous state in
two exomes of European origin in the ExAC dataset. Capil-
lary sequencing in the parents demonstrated a compound-
heterozygous state of both alleles. The Re´union allele was
inherited from the mother, who turned out to have been
born in Re´union, and the other allele came from the father.
We further excluded structural variations at the locus by
performing whole-genome sequencing in two affected in-
dividuals from Re´union. We generated, on average, 115.5
Gb of sequence, resulting in an average depth of coverage
of 32 and in 89% of the coding regions’ of the RefSeq
collection being covered at least 20 times. In addition,828 The American Journal of Human Genetics 96, 826–831, May 7, 2this analysis revealed no evidence for a deletion of any of
the coding exons in the critical region.
Homozygous or compound-heterozygous occurrence of
rareMARS variants was only infrequently observed in con-
trol individuals. Our in-house exomes contained only one
additional exome carrying a homozygous MARS missense
variant, c.2180G>A (p.Arg727Gln; rs113808165; MAF ¼
0.55%), and one compound-heterozygous carrier of the
same variant (rs113808165) in combination with the
missense variant c.617C>T (p.Pro206Leu; rs138776588;
MAF ¼ 0.5%). The two individuals carrying these variants
were diagnosed with myocardial infarction and ventricular
arrhythmia, respectively. Both missense variants were pre-
dicted to be benign by PolyPhen-2 and SIFT. A conservative
test comparing the three homozygous or compound-het-
erozygous variants in the affected individuals with the
two homozygous variants found in 4,000 control subjects
found the differences to be highly significant (Fisher’s
exact test: p < 1.9e8).
MARS codes for the methionyl-tRNA synthetase, which
belongs to the class 1 family of aminoacyl-tRNA synthe-
tases (ARSs). These enzymes play a critical role in protein
biosynthesis by charging tRNAs with their cognate amino
acids. MARS is a component of a multi-protein complex
and catalyzes the ligation of methionine to tRNA mole-
cules. The protein is highly conserved and ubiquitously ex-
pressed. Structural prediction of human methionyl-tRNA
synthetase (Figure 1 and Figures S3 and S4) showed that
Tyr344 and Ser567 lie in theMARS Rossman fold, a domain
that contains most of the sites that catalyze both the me-
thionyl adenylation from L-methionine and ATP and the
methionylation of the tRNAMet. Ala393 lies in a loop in
the connective polypeptide, downstream of the first of
four conserved CXX[C,D,H] motifs that are involved in
the binding of two zinc ions. Asp605 lies in the stem-con-
tact fold domain, which contains both a region that binds
to the inside of the L-shaped tRNA and sites that catalyze
the methionyl adenylation.11–13
Because of the fundamental role of ARSs in cell meta-
bolism, the identified variants most likely result in reduced
enzyme activity rather than a complete loss of that activity.
Taking advantage of the conservation of MARS between
humans and yeast, we assessed enzyme activity of the015
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Figure 2. Growth of MES1Wild-Type and mes1 Mutant Strains
Growth (A) without methionine or (B) with 20 mg/ml methionine.
Cells were inoculated at the concentration of 0.1 OD600/ml and
grown until the stationary phase was reached after 28 hr. At regu-
lar intervals, aliquots were used for measurement of cell density by
UV-visible spectrophotometry at 600 nm. Sampling times are indi-
cated by x-axis ticks. Tables show division times (minutes) calcu-
lated during the exponential phase of growth. Division times are
the mean of three independent growth curves. The S. cerevisiae
strain used in this work was W303-1B (Mata ade2-1 leu2-3,112
ura3-1 trp1-1 his3-11,15 can1-100). The MES1 wild-type allele
was cloned in the centromeric vector pFL3814. Genomic MES1
was disrupted in the pFL38MES1-transformed W303-1B strain by
one-step gene disruption with a KanMX expression cassette.15
mes1 mutant and double-mutant alleles were constructed via
site-directed mutagenesis through the PCR overlap extension
technique with the oligonucleotides listed in Table S4,16 cloned
into vector pFL3914, and introduced into W303-1B mes1D
pFL38MES1. In a second step, strains devoid of pFL38MES1WT
and containing the pFL39-borne MES1WT or mes1 mutant alleles
were selected through plasmid shuffling.17 NS, not significant in
a two-tailed, unpaired t test; **p < 0.01.mutated alleles by both growth of wild-type and mutant
strains and methionine-incorporation assays in yeast by
expressing the variants in the yeast orthologMES1 (Figures
2A and 3A and Figures S5 and S6). Activities of the mutated
alleles were compared with the wild-type and the human-
ized alleles in case the amino acid was not conserved be-
tween human and yeast (Table 2). Compared with those
in wild-type yeast, enzyme activities in humanized alleles
were not significantly different. However, compared to
those of the wild-type or respective humanized alleles,
both calculated division times and 35S incorporation
were significantly different in yeast transfected with the
mutated alleles, with the exception of mes1Asn325Thr, one
of the two variants found in the individuals from Re´union.
Although mes1Asn325Thr alone does not attenuate enzyme
activity, it worsens the phenotype if it is expressed inThe Amcombination with mes1Ser499Leu. Of note, attenuation of
enzyme activity occurs in a liquid medium without methi-
onine, and its activity can be restored in a medium supple-
mented with 20 mg/ml methionine (Figures 2B and 3B).
This observation, together with the predicted position of
the mutated amino acids inside the protein, renders inter-
ference of the variants with substrate binding the most
likely functional mechanism.
We have provided convincing genetic and functional
evidence that MARS mutations are the cause of a specific
type of PAP. We delineated a 530-kb candidate region by
performing homozygosity mapping in 14 affected individ-
uals from Re´union. Within this candidate region, exome
and genome sequences helped to identify two rare homo-
zygous missense variants in close proximity in a single
gene, MARS. Three other non-synonymous variants in
this region had an allele frequency of at least 0.21 and
are therefore unlikely to be disease causing. Themost likely
disease-causing variant, p.Ser567Leu, was found in all 26
investigated affected individuals, had a frequency of only
4 in approximately 60,000 control samples in the ExAC
dataset, and was not present in 4,000 in-house control
samples. We further excluded structural variations in this
region by genome sequencing. Next, we identified a
different homozygous MARS missense variant in two
affected siblings from Tunisia and compound-heterozy-
gous variants, one of which was identical to the Re´union
haplotype, in a French individual with sporadic PAP. The
variants p.Ala393Thr and p.Ser567Leu are in strong link-
age disequilibrium in the Re´union population, therefore
hampering a conclusion about their causality for PAP.
Functional investigation in yeast provided evidence that
p.Ser567Leu is disease causing given that the correspond-
ing mutation in yeast resulted in reduced growth and
more than a 50% reduction of methionine incorporation,
whereas the mutation corresponding to p.Ala393Thr did
not show a phenotype. This interpretation is further sup-
ported by data from the East Asian population where the
p.Ala393Thr variant is present in 19 of 8,654 alleles,
whereas p.Ser567Leu is absent. However, the possibility
that p.Ala393Thr contributes to the phenotype cannot
be excluded, given that the corresponding mutation in
yeast aggravated the phenotype of the mutation corre-
sponding to p.Ser567Leu in a double-mutation strain. We
assessed the functional impact of the mutations by con-
ducting yeast complementation studies. Confirmation by
aminoacylation assays might be worthwhile. However,
the validity of yeast assays has been shown during the
investigation of several other ARS mutations in which an
attenuated function demonstrated in yeast was confirmed
by aminoacylation assays.18 The human genome harbors
37 ARS loci. 17 encode a cytoplasmic enzyme, 17 a mito-
chondrial enzyme, and 3 a bi-functional enzyme that is
present in both cell compartments.18 Thus far, ARS muta-
tions have been implicated in autosomal-recessive mito-
chondrial disease and autosomal-dominant peripheral
neuropathies known as Charcot-Marie-Tooth disease.18erican Journal of Human Genetics 96, 826–831, May 7, 2015 829
AB
Figure 3. 35S Incorporation ofMES1Wild-Type andmes1Mutant
Strains
Incorporation (A) without methionine or (B) with 20 mg/ml
methionine. Values are normalized to the wild-type strain, which
was set as 100%. Four replicates were performed for the ex-
periments without methionine and three replicates for the
experiments with methionine. The error bars indicate SDs. Cells
were inoculated at a final concentration of 0.1 OD600/ml in
synthetic-complete-dextrose medium (0.69% yeast nitrogen
base, 0.1% yeast amino acid and nucleobase mixture, 2% glucose)
with or without 20 mg/ml methionine and grown at 37C.
After 16 hr, cells were diluted to a final concentration of 1.2
OD600/ml. After 5 min, cells were supplemented with 1 ml, if
grown without methionine, or 10 ml, if grown with methionine,
of EasyTag [35S]-protein labeling mix having a specific activity
of 1,000 Ci/mmol (Perkin Elmer). Once we verified that the
incorporation signal was linear between 2 and 10 min, we
blocked protein synthesis after 6 min by adding a mix con-
taining 200 mg cycloheximide, 1 mg erythromycin, 100 mg cold
L-methionine, and 100 mg cold L-cysteine and chilling the
mixture on ice. We used the trichloroacetic (TCA) method to
precipitate total proteins by chilling the cells supplemented
with 25% TCA on ice, then resuspended the proteins in 30 ml
of 60-mM Tris-HCl (pH 6.8). For each sample, counts per
minute/OD600 were measured on 10 ml aliquots and normalized
Table 2. Variants Introduced into Mes1 for the Studies in Yeast
MARS Variant Mes1 Variant Humanized Mes1
p.Ala393Thr p.Asn325Thr p.Asn325Ala
p.Ser567Leu p.Ser499Leu NA
p.Asp605Val p.Asn537Val p.Asn537Asp
p.Tyr344Cys p.Tyr276Cys NA
Human transcript NM_004990.3 and yeast protein P00958 were used as refer-
ence sequences. The following abbreviation is used: NA, not applicable.
830 The American Journal of Human Genetics 96, 826–831, May 7, 2Here, we add a further phenotype to the wide spectrum of
tissue-specific human diseases caused by ARS mutations. A
single female infant has previously been reported to carry
compound-heterozygous MARS mutations (c.1108T>C
[p.Phe370Leu] and c.1568T>C [p.Ile523Thr]).19 The
described phenotype is compatible with that observed in
this study; however, it seems to include additional signs
such as acidosis, aminoaciduria, hypothyroidism, and ane-
mia (MIM: 615486). In addition, rare heterozygous MARS
variants have been reported in individuals affected by
late-onset Charcot-Marie-Tooth disease.20,21 In this study,
however, family history of index patients in Re´union
does not provide any evidence that heterozygous carriers
are affected by Charcot-Marie-Tooth disease. Studies in
yeast have demonstrated that attenuation ofMARS activity
could be rescued by supplementation with methionine. To
our knowledge, a similar effect has only been described for
a VARS2 mutation before.22 This observation suggests the
need for investigation of potential beneficial effects of
high-dose methionine treatment in humans.Accession Numbers
The ClinVar accession numbers for the three sequence variants re-
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